May 17, 2020

Novo Nordisk faces drug pricing issues

Admin
3 min
Novo Nordisk faces drug pricing issues.jpg
Written by Alyssa Clark The worlds largest insulin producer Novo Nordisk, has been faced with a new set of complicated problems concerning its ability...

Written by Alyssa Clark 

 

The world’s largest insulin producer Novo Nordisk, has been faced with a new set of complicated problems concerning its ability to price its products. The seemingly unstoppable growth has begun to worry some of the firm’s chief executives, especially Lars Sorensen. Though there is now a flag raised concerning the pricing issue, Sorensen reassures his company and the public that the number of potential customers for his products will keep rising; with the global obesity epidemic close at hand, more people are falling into the type 2 diabetes disease in the West and in developing nations as well.

Problems concerning the pricing of insulin and other diabetes treatments are where the conflict truly lies for Sorensen and those at Novo Nordisk. Cost-conscious reimbursement authorities around the world as constantly being challenged for what determines a good and fair price for these lifesaving drugs.  

“Pricing is going to be challenging”, Sorensen said in an interview at the drugmaker's headquarters in Bagsvaerd on the outskirts of Copenhagen, where a new spiral office complex inspired by the insulin molecule is under construction.

“In Europe, it is already a challenge and pricing in the United States is likely to be challenging in the future as well, with healthcare reform and concentration in the distribution chain”.

As of last week, the group held its double-digit percentage sales growth, which is a goal that most of the drugmakers in competition with Novo Nordisk dream of. These results however were not up to the goals which Sorensen and others had set for their company; this sparked a warning sign that profits might only grow high in single digits in 2014. This would be a result of unnerved investors who have bought into Novo over the years because of this sustained, long-term growth.

Sorensen says that Novo still has its sights set on the goal of 15 percent profit growth, and that sales growth is “always conservative” and is “still there, alive and kicking”.  He admits though that it is tougher to grow the Nordic region after the FDA decided to delay the approval of the new long-acting insulin drug Tresiba. This delay from the FDA allows for competitors within the industry to make moves within the market; Sanofi’s new insulin U300 and Eli Lilly threaten the Novo Nordisk’s place as the market “favorite” with their non-insulin based diabetes drug Victoza.

"We need to price innovation at a premium, otherwise we will not be able to fund innovation going forward," Sorensen said.

"We could have priced ourselves into the (Express Scripts) contract had we wanted to, but we believe Victoza is a better product and therefore demands a premium."

 

About the Author

Alyssa Clark is the Editor of Healthcare Global

Share article

Jun 15, 2021

Why are healthcare networks so vulnerable to attacks? 

Cybersecurity
IoT
healthcarenetwork
cyberattacks
5 min
Elisa Costante from Forescout Technologies gives us the lowdown on how vulnerabilities in the healthcare sector happen, and how to secure them

Forescout Research Labs has published a study on the vulnerabilities impacting the healthcare industry’s connected devices. The research division of Forescout Technologies has published the report as part of its Project Memoria, and it reveals that healthcare organisations are affected five times more by TCP/IP vulnerabilities than any other sector. 

Elisa Costante, a software engineer and Forescout's Vice President of Research, explains why this is and how to prevent it. 

What is Project Memoria? 
Project Memoria aims to improve the security of TCP/IP stacks and understand what  the main security issues are. TCP/IP stacks are a very core component of every network device, whether it's an iPhone connected to the internet, or a robot controlling  the process of manufacturing. If they're connected to the internet they need to have a piece of software controlling communication. 

There are several variants of this software and we're analysing them to understand if they have security bugs or vulnerabilities that if misused by attackers, could lead to disruption of the device itself, and to the network at large. Our goal is to make the industry aware of the problem, and engage with stakeholders as well as the customers. 

Why is healthcare particularly vulnerable? 
This is what the data is telling us. We have a device cloud, which is like a data lake of device information. This device cloud has a lot of information about the devices, like who the vendor is, what the role of the network is, and which vertical this is. We are able to leverage this information, and join it with the intelligence we have from Project Memoria to understand which devices are vulnerable. 

We found that in healthcare there was a huge spike in the number of devices that are vulnerable - as much as  five times more than in other verticals. The reason seems to be because of the number of devices, and because of the intrinsic difficulty of addressing the problem. 

The problem surrounding TCP/IP stacks is that there is not one single vendor that is vulnerable; on average, a healthcare organisation has 12 vendors that are vulnerable. 
Let's say that on average we have 500 devices per healthcare organisation.  Then you need to contact 12 vendors for each of these. These vendors then need to issue a patch to secure the device, and this patch cannot just be automatically delivered and installed in 500 devices. You have to be realistic and think about whether each of the devices  is critical, for example if it goes down will it turn the lighting system off, or stop the MRI machine from working. 

Patches are very complex to deploy. On top of that, the patch needed might not even be available.  That's why we want to understand this problem better  so we can provide solutions. 

How much of the responsibility of keeping a device secure lies with the vendor? 
There are responsibilities that lie with all the different stakeholders, and one of these is  the vendor. There might be multiple vendors involved, which makes it very complex  from a management perspective. 

For instance the device at the end of the chain, which might be an MRI, contains a board that has a connectivity module, and this has one of the stacks that is vulnerable, which could have four different vendors. 

If the vendor responsible for the TCP/IP stack releases a patch, this patch has to go down the chain. We identified chains with a length of six vendors, so you can imagine how complex this is. Some vendors have good hygiene security and some don't because they don't know how to deal with it - they need training. 

This is a new issue related to the software bill of materials, which is being tabled for legislation at the moment to create policies regarding the complexity of the supply chain. We need to shed light on this issue so that legislators can put these policies in place to help with security.  

What can healthcare providers do themselves to stay secure? 
Visibility is important; they need to know what they have in their network. In the case of vulnerable devices they should find out if there's a patch available. If there isn't, because it's an old device for example, but it's still critical to the system, they may want to isolate it so it only communicates with the devices it really needs to. 

Interestingly enough, our research found that most of the healthcare organisations we analysed had a flat network, which means they don't have isolated devices. For instance, a drugs dispensing machine, which you typically find in pharmacies,  is connected to a building automation light system, which is connected to a switch. This is also connected to an IoT sensor device. Why would you have all of them together in the same place? 
The first step is having this information, which often comes as a surprise. Then you can take action; you can segment a network, and if you can't do that you can control the network's access by isolating devices that are risky.

How can Forescout help healthcare organisations? 
Forescout is uniquely positioned to help. We provide visibility end-to-end, which means having a full inventory of devices that includes quite granular detail, so they can know what the operating system is, who the vendor is and so on. Then we enable them to do network segmentation. 

This enables organisations to write policies around how to secure their networks, for example if a device is vulnerable specify which connected devices must be isolated, or which device it must communicate with exclusively. 

Share article